Paul E Croarkin1, Paul A Nakonezny2, Mustafa M Husain3, John D Port4, Tabatha Melton3, Betsy D Kennard3, Graham J Emslie3, F Andrew Kozel5, Zafiris J Daskalakis6. 1. Department of Psychiatry and Psychology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA. Electronic address: croarkin.paul@mayo.edu. 2. Department of Clinical Sciences, Division of Biostatistics, UT Southwestern Medical Center, Dallas, TX, USA. 3. Department of Psychiatry, UT Southwestern Medical Center, Dallas, TX, USA. 4. Department of Radiology, Mayo Clinic, Rochester, MN, USA. 5. Department of Psychiatry and Behavioral Neurosciences, University of South Florida, Tampa, FL, USA. 6. Brain Stimulation Treatment and Research Unit, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Abstract
BACKGROUND: Research suggests that alterations in gamma-aminobutyric acid receptor functioning have a role in depression. Paired-pulse transcranial magnetic stimulation (TMS) paradigms are noninvasive measures of cortical inhibitory and excitatory circuits. OBJECTIVE/HYPOTHESIS: The present study examined pretreatment short-interval intracortical inhibition (SICI), long-interval cortical inhibition (LICI), and intracortical facilitation (ICF) in children and adolescents with major depressive disorder who were initiating fluoxetine treatment. The primary objective was to examine the relationship of these measures with subsequent treatment response. It was hypothesized that alterations in pretreatment GABA and glutamate mediated neurotransmission, would be associated with fluoxetine nonresponse. METHODS: Sixteen children and adolescents with major depressive disorder underwent paired-pulse TMS testing before beginning fluoxetine treatment. Response was prospectively characterized by scores of 1 or 2 on the Clinical Global Impression Scale and less than 40 on the Children's Depression Rating Scale-Revised after 6 weeks of fluoxetine treatment (20-40 mg/day). RESULTS: Eight patients responded to treatment. Least-squares mean LICI values were consistently higher bilaterally for treatment nonresponders. Higher LICI values indicate less inhibition and impaired GABAB functioning. There was no significant effect of treatment response on the measures of SICI and ICF. CONCLUSIONS: Our findings suggest that deficits in pretreatment GABAB may be related to fluoxetine nonresponse in depressed youth. This is congruent with prior work demonstrating that GABAB interneurons have serotonergic input and antidepressants modulate GABAB receptors. These findings also show that TMS paradigms have utility in studying the neurophysiology and treatment of childhood mood disorders. REGISTRATIONS: Cortical Excitability and Inhibition in Children and Adolescents With Major Depressive Disorder, http://www.clinicaltrials.gov/ct2/show/NCT00896090?term=cortical+excitability+and+inhibition&rank=2, NCT00896090; Sequential Treatment of Pediatric MDD to Increase Remission and Prevent Relapse, http://www.clinicaltrials.gov/ct2/show/NCT00612313?term=Sequential+Treatment+and+MDD&rank=1, NCT00612313.
BACKGROUND: Research suggests that alterations in gamma-aminobutyric acid receptor functioning have a role in depression. Paired-pulse transcranial magnetic stimulation (TMS) paradigms are noninvasive measures of cortical inhibitory and excitatory circuits. OBJECTIVE/HYPOTHESIS: The present study examined pretreatment short-interval intracortical inhibition (SICI), long-interval cortical inhibition (LICI), and intracortical facilitation (ICF) in children and adolescents with major depressive disorder who were initiating fluoxetine treatment. The primary objective was to examine the relationship of these measures with subsequent treatment response. It was hypothesized that alterations in pretreatment GABA and glutamate mediated neurotransmission, would be associated with fluoxetine nonresponse. METHODS: Sixteen children and adolescents with major depressive disorder underwent paired-pulse TMS testing before beginning fluoxetine treatment. Response was prospectively characterized by scores of 1 or 2 on the Clinical Global Impression Scale and less than 40 on the Children's Depression Rating Scale-Revised after 6 weeks of fluoxetine treatment (20-40 mg/day). RESULTS: Eight patients responded to treatment. Least-squares mean LICI values were consistently higher bilaterally for treatment nonresponders. Higher LICI values indicate less inhibition and impaired GABAB functioning. There was no significant effect of treatment response on the measures of SICI and ICF. CONCLUSIONS: Our findings suggest that deficits in pretreatment GABAB may be related to fluoxetine nonresponse in depressed youth. This is congruent with prior work demonstrating that GABAB interneurons have serotonergic input and antidepressants modulate GABAB receptors. These findings also show that TMS paradigms have utility in studying the neurophysiology and treatment of childhood mood disorders. REGISTRATIONS: Cortical Excitability and Inhibition in Children and Adolescents With Major Depressive Disorder, http://www.clinicaltrials.gov/ct2/show/NCT00896090?term=cortical+excitability+and+inhibition&rank=2, NCT00896090; Sequential Treatment of Pediatric MDD to Increase Remission and Prevent Relapse, http://www.clinicaltrials.gov/ct2/show/NCT00612313?term=Sequential+Treatment+and+MDD&rank=1, NCT00612313.
Authors: Irena Balzekas; Charles P Lewis; Julia Shekunov; John D Port; Gregory A Worrell; Hang Joon Jo; Paul E Croarkin Journal: Psychiatry Res Neuroimaging Date: 2018-05-31 Impact factor: 2.376
Authors: Bahar Salavati; Tarek K Rajji; Reza Zomorrodi; Daniel M Blumberger; Robert Chen; Bruce G Pollock; Zafiris J Daskalakis Journal: Neuropsychopharmacology Date: 2017-05-29 Impact factor: 7.853
Authors: Olivia F O'Leary; Daniela Felice; Stefano Galimberti; Hélène M Savignac; Javier A Bravo; Tadhg Crowley; Malika El Yacoubi; Jean-Marie Vaugeois; Martin Gassmann; Bernhard Bettler; Timothy G Dinan; John F Cryan Journal: Proc Natl Acad Sci U S A Date: 2014-10-06 Impact factor: 11.205
Authors: Camila B Pinto; Faddi G Saleh Velez; Fernanda Lopes; Polyana V de Toledo Piza; Laura Dipietro; Qing M Wang; Nicole L Mazwi; Erica C Camargo; Randie Black-Schaffer; Felipe Fregni Journal: Front Neurosci Date: 2017-11-16 Impact factor: 4.677
Authors: Jonathan C Lee; Paul E Croarkin; Stephanie H Ameis; Yinming Sun; Daniel M Blumberger; Tarek K Rajji; Zafiris J Daskalakis Journal: Front Psychiatry Date: 2017-05-29 Impact factor: 4.157
Authors: Jennifer I Lissemore; Benoit H Mulsant; Anthony J Bonner; Meryl A Butters; Robert Chen; Jonathan Downar; Jordan F Karp; Eric J Lenze; Tarek K Rajji; Charles F Reynolds; Reza Zomorrodi; Zafiris J Daskalakis; Daniel M Blumberger Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2021-07-23
Authors: Parmis Fatih; M Utku Kucuker; Jennifer L Vande Voort; Deniz Doruk Camsari; Faranak Farzan; Paul E Croarkin Journal: Front Psychiatry Date: 2021-06-02 Impact factor: 4.157
Authors: Paul E Croarkin; Paul A Nakonezny; Charles P Lewis; Michael J Zaccariello; John E Huxsahl; Mustafa M Husain; Betsy D Kennard; Graham J Emslie; Zafiris J Daskalakis Journal: Front Hum Neurosci Date: 2014-09-02 Impact factor: 3.169